Gary Rieschel is the Founding Managing Partner of Qiming Venture Partners, a firm he launched in Shanghai in 2006. Qiming invests in Technology and Consumer (T&C) and Healthcare and has 70 staffs in China and the U.S. Qiming has $9.4 billion USD in capital raised. Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan Dianping (SEHK:3690), UBTech, Bilibili (NASDAQ:BILI), Roborock (SHSE:688169), Tigermed (SZSE:300347), Zai Lab (NASDAQ:ZLAB), Venus MedTech (SEHK:2500), CanSino (SEHK:6185), Schrödinger (NASDAQ:SDGR), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), WeDoctor Group among many others.
Prior to founding Qiming, Mr. Rieschel was a senior executive at Intel, Sequent Computer, Cisco Systems, and Softbank Corporation. Gary started his VC career by creating Softbank’s U.S. venture group in 1995 (SBVC), and while at Softbank he invested in twelve companies which grew to over $1B USD in market capitalization and served on Softbank’s board of directors. Gary was early in the emergence of venture capital in China, through sponsoring and founding several of China’s early VC firms, including Softbank China Ventures (2000), SAIF Partners (2001), and Ceyuan Ventures (2004), before moving to China to create Qiming.
Mr. Rieschel is well regarded as a mentor to entrepreneurs and other venture capitalists. He helped found the China Greentech Initiative, and he sponsored the Rocky Mountain Institute’s entry to China (Re-Inventing Fire – China). Gary actively supports the Asia Society, the Council on Foreign Relations, The Nature Conservancy, PERC (free market environmentalism), the Climate Leadership Council, and the U.S. Olympic Foundation. He is on the Fudan University International Advisory Board.
Mr. Rieschel attended Reed College (BA Biology) and Harvard Business School (MBA). Mr. Rieschel was based in Shanghai from 2005 through 2016 when he relocated to Seattle, WA to launch the Qiming U.S. operations.
